The treatment landscape for multiple sclerosis continues to get more complex month to month, which makes biomarker discovery increasingly important for treating the disease, said Suhayl Dhib-Jalbut, MD, professor at the Rutgers University Robert Wood Johnson Medical School, during his session at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston, Massachusetts.
The treatment landscape for multiple sclerosis (MS) continues to get more complex month to month, which makes biomarker discovery increasingly important for treating the disease, according to Suhayl Dhib-Jalbut, MD, professor at the Rutgers University Robert Wood Johnson Medical School.
There are many significant reasons why biomarker discovery in MS is crucial, including early diagnosis, assessing disease activity, and predicting treatment response and treatment complications, Dhib-Jalbut said during his talk “Biomarkers of Treatment Response to MS Disease Therapies,” at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston, Massachusetts from September 10-13.
For instance, alemtuzumab — which is not available in the United States, but is available elsewhere in the world — is associated with autoimmune complications in patients.
The biomarkers that are known to be clinically useful for monitoring MS therapy include:
Biomarker
Condition
JC virus assay
Progressive multifocal leukoencephalopathy risk with natalizumab
Neutralizing antibodies
Interferon unresponsiveness
HLA DR & DQ alleles, transforming growth factor beta/interleukin (IL)-18
Glatiramer response
IL-10/IL-17/interferon-beta
Interferon response
IL-21
Alemtuzumab autoimmunity
CD 56Bright
Daclizumab therapy
MRI
Interferon response
However, disease heterogeneity is a challenge to biomarker discovery, according to Dhib-Jalbut. For instance, the disease is pathologically heterogeneous, there are inconsistent immune findings, and variable clinical courses.
Furthermore, the fact that response to disease-modifying drugs varies from patient to patient is not only important to keep in mind when choosing which therapy to use, but it makes finding new biomarkers difficult, he said.
During his talk, Dhib-Jalbut highlighted potentially useful biomarkers such as the VLA-4 integrin, CD34 cells, and cerebral spinal fluid, for natalizumab. Also, the CD4:CD8 ratio and decreased T-cells or B-cells could be useful with fingolimod.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More